# The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

> **NCT00000981** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 78 (—)

## Conditions studied

- Cytomegalovirus Infections
- HIV Infections

## Interventions

- **DRUG:** Fiacitabine

## Key facts

- **NCT ID:** NCT00000981
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1993-02
- **Target enrollment:** 78 (—)
- **Last updated:** 2012-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000981, "The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*